AI413597; AW045860; DDPAC; FLJ31424; FTDP 17; G protein beta1/gamma2 subunit interacting factor 1; MAPT; MAPTL; MGC134287; MGC138549; MGC156663; Microtubule associated protein tau; Microtubule associated protein tau isoform 4; Microtubule-associated protein tau; MSTD; Mtapt; MTBT1; MTBT2; Neurofibrillary tangle protein; Paired helical filament tau; Paired helical filament-tau; PHF tau; PHF-tau; PPND; PPP1R103; Protein phosphatase 1, regulatory subunit 103; pTau; RNPTAU; TAU; TAU_HUMAN; Tauopathy and respiratory failure, included;
WB 1:500-1:2000, IHC 1:100-1:500, ELISA(peptide) 1:20000-1:40000
*The optimal dilutions should be determined by the end user.
Human, Mouse, Rat
Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(100%)
Rabbit
Polyclonal
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
Phospho-Tau (Ser396) Antibody detects endogenous levels of Tau only when phosphorylated at Serine 396.
AB_2834583
Please cite this product as: Affinity Biosciences Cat# AF3148, RRID:AB_2834583.
Liquid
1mg/ml
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt.
A synthesized peptide derived from human Tau around the phosphorylation site of Ser396.
>>Visit The Human Protein Atlas
MAPT
Observed Mol.Wt.: 50-80kD.
Predicted Mol.Wt.: 79kDa(Calculated)..
Cytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
P10636 TAU_HUMAN:
Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.
This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type.
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQEPESGKVVQEGFLREPGPPGLSHQLMSGMPGAPLLPEGPREATRQPSGTGPEDTEGGRHAPELLKHQLLGDLHQEGPPLKGAGGKERPGSKEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAAREATSIPGFPAEGAIPLPVDFLSKVSTEIPASEPDGPSVGRAKGQDAPLEFTFHVEITPNVQKEQAHSEEHLGRAAFPGAPGEGPEARGPSLGEDTKEADLPEPSEKQPAAAPRGKPVSRVPQLKARMVSKSKDGTGSDDKKAKTSTRSSAKTLKNRPCLSPKHPTPGSSDPLIQPSSPAVCPEPPSSPKYVSSVTSRTGSSGAKEMKLKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK1, CDK1, CDK5, GSK3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in the form associated with paired helical filaments (PHF-tau)), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK1, MARK2, MARK3 or MARK4), causing detachment from microtubules, and their disassembly. Phosphorylation decreases with age. Phosphorylation within tau/MAP's repeat domain or in flanking regions seems to reduce tau/MAP's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis. Phosphorylation at Ser-548 by GSK3B reduces ability to bind and stabilize microtubules. Phosphorylation at Ser-579 by BRSK1 and BRSK2 in neurons affects ability to bind microtubules and plays a role in neuron polarization. Phosphorylated at Ser-554, Ser-579, Ser-602, Ser-606 and Ser-669 by PHK. Phosphorylation at Ser-214 by SGK1 mediates microtubule depolymerization and neurite formation in hippocampal neurons. There is a reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes the O-GlcNAcylation on this site, while phosphorylation on Ser-713 and Ser-721 reduces glycosylation by a factor of 2 and 4 respectively. Phosphorylation on Ser-721 is reduced by about 41.5% by GlcNAcylation on Ser-717. Dephosphorylated at several serine and threonine residues by the serine/threonine phosphatase PPP5C.
Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
O-glycosylated. O-GlcNAcylation content is around 8.2%. There is reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes the O-GlcNAcylation on this site, while phosphorylation on Ser-713 and Ser-721 reduces O-GlcNAcylation by a factor of 2 and 4 respectively. O-GlcNAcylation on Ser-717 decreases the phosphorylation on Ser-721 by about 41.5%.
Glycation of PHF-tau, but not normal brain TAU/MAPT. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
Cytoplasm>Cytosol. Cell membrane>Peripheral membrane protein>Cytoplasmic side. Cytoplasm>Cytoskeleton. Cell projection>Axon. Cell projection>Dendrite.
Note: Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.
Interacts with MARK1, MARK2, MARK3 AND MARK4. Interacts with PSMC2 through SQSTM1 (By similarity). Interacts with SQSTM1 when polyubiquitinated. Interacts with FKBP4 (By similarity). Binds to CSNK1D. Interacts with SGK1. Interacts with EPM2A; the interaction dephosphorylates MAPT at Ser-396. Interacts with PIN1. Interacts with LRRK2.
The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
· Environmental Information Processing > Signal transduction > MAPK signaling pathway.(View pathway)
· Human Diseases > Neurodegenerative diseases > Alzheimer's disease.
Application: WB Species:mouse; Sample:brain
Fig. 1. The expression A and P-Tau. Representative immunoblots of A and P-Tau in the cortex (A-C) and hippocampus (D-F) in each group. Protein immunoreactivity was normalized to -actin. Individual data are presented as the mean ± S.E.M. from four individual mice in each group.
AF3148-BP
(Blocking peptide available as AF3148-BP)
$350/1mg.
Tips: For phospho antibody, we provide phospho peptide(0.5mg) and non-phospho peptide(0.5mg).
Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (immunoblot) and immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or immunostaining performed with the neutralized antibody.
Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.The purity is >90%,tested by HPLC and MS.Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.
This product is for research use only. Not for use in diagnostic or therapeutic procedures.
Site | PTM Type | Enzyme | Source |
---|---|---|---|
A2 | Acetylation | Uniprot | |
Y18 | Phosphorylation | P06241 (FYN) , P43405 (SYK) | Uniprot |
T39 | Phosphorylation | Uniprot | |
S46 | Phosphorylation | Uniprot | |
T50 | Phosphorylation | Uniprot | |
S56 | Phosphorylation | Uniprot | |
S61 | Phosphorylation | Uniprot | |
S171 | Phosphorylation | Uniprot | |
T173 | Phosphorylation | Uniprot | |
S214 | Phosphorylation | O00141 (SGK1) | Uniprot |
S232 | Phosphorylation | Uniprot | |
S235 | Phosphorylation | Q00535 (CDK5) | Uniprot |
S238 | Phosphorylation | Uniprot | |
S255 | Phosphorylation | Q13131 (PRKAA1) | Uniprot |
S355 | Phosphorylation | Q13131 (PRKAA1) | Uniprot |
S369 | Phosphorylation | Q13627 (DYRK1A) | Uniprot |
T386 | Phosphorylation | Uniprot | |
S388 | Phosphorylation | Uniprot | |
S396 | Phosphorylation | P49841 (GSK3B) , Q13131 (PRKAA1) , P48730 (CSNK1D) | Uniprot |
S400 | Phosphorylation | P49841 (GSK3B) | Uniprot |
S411 | Phosphorylation | Uniprot | |
T449 | Phosphorylation | Uniprot | |
S451 | Phosphorylation | Uniprot | |
T466 | Phosphorylation | Uniprot | |
T470 | Phosphorylation | Uniprot | |
T492 | Phosphorylation | Uniprot | |
T498 | Phosphorylation | P53779 (MAPK10) , P45983 (MAPK8) , P49841 (GSK3B) , Q00535 (CDK5) , P45984 (MAPK9) | Uniprot |
S501 | Phosphorylation | Uniprot | |
S502 | Phosphorylation | Uniprot | |
S508 | Phosphorylation | Uniprot | |
S512 | Phosphorylation | P49841 (GSK3B) | Uniprot |
Y514 | Phosphorylation | Uniprot | |
S515 | Phosphorylation | P49841 (GSK3B) , Q5TCY1 (TTBK1) | Uniprot |
S516 | Phosphorylation | Q00535 (CDK5) , Q5TCY1 (TTBK1) , P45984 (MAPK9) , P53779 (MAPK10) , P49841 (GSK3B) , P45983 (MAPK8) | Uniprot |
S519 | Phosphorylation | Q13627 (DYRK1A) , P53779 (MAPK10) , P45983 (MAPK8) , P48730 (CSNK1D) , Q5TCY1 (TTBK1) , Q00535 (CDK5) , P49841 (GSK3B) , P45984 (MAPK9) , P28482 (MAPK1) | Uniprot |
T522 | Phosphorylation | P45983 (MAPK8) , P48730 (CSNK1D) , P49841 (GSK3B) , Q00535 (CDK5) , P28482 (MAPK1) , P53779 (MAPK10) | Uniprot |
S525 | O-Glycosylation | Uniprot | |
S525 | Phosphorylation | Uniprot | |
S527 | Phosphorylation | Uniprot | |
T529 | Phosphorylation | P45984 (MAPK9) , Q8IWQ3 (BRSK2) , P45983 (MAPK8) , P49841 (GSK3B) , Q8TDC3 (BRSK1) , Q13627 (DYRK1A) , P53779 (MAPK10) , Q92630 (DYRK2) , P57059 (SIK1) , Q00535 (CDK5) | Uniprot |
S531 | Phosphorylation | P49841 (GSK3B) , P57059 (SIK1) , P17612 (PRKACA) , Q00535 (CDK5) | Uniprot |
T534 | Phosphorylation | Q00535 (CDK5) , P53779 (MAPK10) , P49841 (GSK3B) , P45983 (MAPK8) | Uniprot |
T537 | Phosphorylation | Uniprot | |
T548 | Phosphorylation | P45984 (MAPK9) , Q9UQM7 (CAMK2A) , P17612 (PRKACA) , P49841 (GSK3B) , Q00535 (CDK5) | Uniprot |
S552 | Phosphorylation | Q9UQM7 (CAMK2A) , Q00535 (CDK5) | Uniprot |
S554 | Phosphorylation | Uniprot | |
S555 | O-Glycosylation | Uniprot | |
S555 | Phosphorylation | Uniprot | |
S558 | Phosphorylation | Uniprot | |
K571 | Ubiquitination | Uniprot | |
S575 | Phosphorylation | Uniprot | |
S579 | Phosphorylation | P57059 (SIK1) , Q9P0L2 (MARK1) , P17612 (PRKACA) , Q8TDC3 (BRSK1) , P49841 (GSK3B) , P49840 (GSK3A) , Q9UQM7 (CAMK2A) , O96017 (CHEK2) , Q8IWQ3 (BRSK2) | Uniprot |
T580 | Phosphorylation | Uniprot | |
S602 | Phosphorylation | Uniprot | |
S610 | Phosphorylation | P57059 (SIK1) | Uniprot |
K611 | Methylation | Uniprot | |
S622 | Phosphorylation | P57059 (SIK1) | Uniprot |
Y627 | Phosphorylation | Uniprot | |
K628 | Acetylation | Uniprot | |
K628 | Ubiquitination | Uniprot | |
S633 | Phosphorylation | Uniprot | |
T636 | Phosphorylation | Uniprot | |
S637 | Phosphorylation | Q16512 (PKN1) | Uniprot |
S641 | Phosphorylation | P49840 (GSK3A) , Q9P0L2 (MARK1) , P57059 (SIK1) | Uniprot |
S669 | Phosphorylation | Uniprot | |
K670 | Ubiquitination | Uniprot | |
S673 | Phosphorylation | Q9P0L2 (MARK1) , P17612 (PRKACA) , P57059 (SIK1) | Uniprot |
K686 | Acetylation | Uniprot | |
K687 | Acetylation | Uniprot | |
T690 | Phosphorylation | Uniprot | |
T694 | Phosphorylation | Uniprot | |
Y711 | Phosphorylation | Uniprot | |
S713 | Phosphorylation | Q00535 (CDK5) , P49840 (GSK3A) , P45984 (MAPK9) , P45983 (MAPK8) , P53779 (MAPK10) , P49841 (GSK3B) | Uniprot |
S717 | O-Glycosylation | Uniprot | |
S717 | Phosphorylation | P49841 (GSK3B) | Uniprot |
T720 | Phosphorylation | Uniprot | |
S721 | Phosphorylation | P45984 (MAPK9) , P49841 (GSK3B) , Q00535 (CDK5) , P45983 (MAPK8) , Q13627 (DYRK1A) , P28482 (MAPK1) , P53779 (MAPK10) , P49840 (GSK3A) , P48730 (CSNK1D) | Uniprot |
S726 | Phosphorylation | P17612 (PRKACA) | Uniprot |
S729 | Phosphorylation | Uniprot | |
S730 | Phosphorylation | Uniprot | |
T731 | Phosphorylation | Uniprot | |
S733 | Phosphorylation | Uniprot | |
S739 | Phosphorylation | P53779 (MAPK10) , P45984 (MAPK9) , P45983 (MAPK8) , Q5TCY1 (TTBK1) | Uniprot |
T744 | Phosphorylation | Uniprot |